Consensus Geron Corporation

Stocks

GERN

US3741631036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-18 EDT			5-day change	1st Jan Change
1.260 ^USD	+2.44%		+9.57%	-4.55%

06-08	Geron Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08:40 AM
05-12	Geron Corporation Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 04:35 PM

Evolution of the Average Target: Geron Corporation

Evolution of the Target Price: Geron Corporation

Changes in Analyst Recommendations: Geron Corporation

39071e8916db7f49c7ec.s-BGJrHd0SAVj_Ll39HpH1sdoB7lDC2yWjcF8tTqxrY.ya0XVN67p1hH-q3diuKYfWNFxn3VZmH6Dm5KqJ2Ov4fnundW9o-LTyDgnQ~153c6164dff8d47a9bf2cd7e4661f932

Analysts' recommendations: Geron Corporation

11-06	Wedbush Cuts Price Target on Geron to $5 From $6, Keeps Outperform Rating	MT
25-05-08	Scotiabank Downgrades Geron to Sector Perform From Sector Outperform, Adjusts Price Target to $1.50 From $4	MT
25-02-27	B. Riley Downgrades Geron to Neutral From Buy, Cuts Price Target to $2 From $3.50	MT
25-02-26	Wedbush Lowers Geron's Price Target to $7 From $8, Outperform Rating Maintained	MT
25-02-26	HC Wainwright Downgrades Geron to Neutral From Buy	MT
25-02-18	B. Riley Adjusts Geron Price Target to $3.50 From $5.50, Maintains Buy Rating	MT
24-10-16	Scotiabank Initiates Geron at Sector Outperform With $6 Price Target	MT
24-09-09	Leerink Partners Initiates Coverage on Geron With Outperform Rating, $7 Price Target	MT
24-08-09	B. Riley Adjusts Price Target on Geron to $5.50 From $5, Maintains Buy Rating	MT
24-06-10	Barclays Initiates Geron at Overweight Rating With $9 Price Target	MT
24-06-10	Stifel Nicolaus Adjusts Geron Price Target to $7 From $6, Maintains Buy Rating	MT
24-06-07	Wedbush Raises Geron's Price Target to $8 From $7, Outperform Rating Maintained	MT
24-06-07	Needham Adjusts Geron Price Target to $6 From $5, Maintains Buy Rating	MT
24-05-03	Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating	MT
24-04-30	Baird Downgrades Geron to Neutral From Outperform, Price Target at $4.50	MT
24-04-29	TD Cowen Initiates Geron With Buy Rating, $10 Price Target	MT
24-03-15	Needham Adjusts Geron's Price Target to $5 From $4, Maintains Buy Rating	MT
24-03-15	Goldman Sachs Adjusts Price Target on Geron to $5 From $4, Keeps Buy Rating	MT
23-09-12	Goldman Sachs Upgrades Geron to Buy From Neutral, Price Target is $4	MT
23-03-28	Goldman Sachs Initiates Geron at Neutral With $3 Price Target	MT
23-01-09	Needham Adjusts Price Target on Geron to $4 From $3, Maintains Buy Rating	MT
23-01-09	B. Riley Lifts Geron's PT to $5 From $4, Keeps Buy Rating After Positive Topline Results From Phase III Trial of Imetelstat	MT
23-01-04	Wedbush Lifts Geron's Price Target to $6 From $5, Keeps Outperform Rating	MT
22-10-28	Wedbush Starts Geron at Outperform With $5 Price Target	MT
22-08-12	Needham & Co Adjusts Geron Price Target to $3 From $2, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GERON CORPORATION					+169.84%
	ARGENX SE					+9.72%
	WUXI APPTEC CO., LTD.					+42.1%
	BIONTECH SE					+36.27%
	INSMED INCORPORATED					+105.79%
	WUXI BIOLOGICS (CAYMAN) INC.					+51.99%
	GENMAB A/S					+41.35%
	EXELIXIS, INC.					-5.61%
	PHARMAESSENTIA CORPORATION					-23.54%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+31.71%
	Average					+45.96%
	Weighted average by Cap.					+33.20%